DENVER--(BUSINESS WIRE)--Apr 24 2007 - Ceragenix PharmaceuticalsInc....The study which took place at five centers consisted of 113pediatri... The data from this study demonstrate that EpiCeram(TM) iseffective a...Atopi...

The study, which took place at five centers, consisted of 113
pediatric patients, with 59 patients receiving treatment with
Cutivate(R) and 54 patients receiving treatment with EpiCeram(TM).
After 28 days of treatment, the study demonstrated that: -0-

Both EpiCeram(TM) and Cutivate(R) produced significant
improvement in patients' conditions after 28 days of treatment;
There were no statistically significant differences between the
groups treated with EpiCeram(TM) compared to those treated with
Cutivate(R) as measured by the SCORAD index at Day 28 (the
primary outcome measure) or in the percentage of patients
assessed to be "clear or almost clear" by physician assessment
at Day 28 (a secondary outcome measure).
Both EpiCeram(TM) and Cutivate(R) produced significant relief
from itching (pruritus) and improvement in sleep habits after
28 days of treatment and that there was no statistically
significant difference between the two treatments in these
measures at this time point (both secondary outcome measures).

"The data from this study demonstrate that EpiCeram(TM) is
effective and offers both the clinician and parents a new approach
for treating atopic dermatitis without the risks often associated
with long-term use of topical steroids or immunosuppressants," said
Lawrence Charles Parish, M.D., Clinical Professor of Dermatology
and Cutaneous Biology at Jefferson Medical College of Thomas
Jefferson University in Philadelphia, one of the study's principal
investigators.

Atopi
c dermatitis is a chronic childhood skin condition that may
affect patients for many years. Dermatology agents currently used
to treat atopic dermatitis and other inflammatory skin disorders
have important limitations and two commonly used immunosuppressants
have been the subject of a controversial FDA imposed "black box"
warning of a potential link between long term use and certain
cancer risks. The use of EpiCeram(TM) does not raise any of the
major safety concerns associated with the use of topical steroids
and immunosuppressants.

Steve Porter, Ceragenix's Chairman and CEO stated, "We are very
pleased with these results. We have just demonstrated that
EpiCeram(TM) is comparable to a mid strength steroid in treating
the symptoms of atopic dermatitis after a 28 day treatment regimen.
We believe that EpiCeram has the potential to become the foundation
of a new and improved paradigm in the treatment of this common
childhood skin disorder which affects over 15 million
Americans."

Study Design

The study was an investigator-blinded, randomized controlled
study conducted at five centers which evaluated a total of 113
patients in two groups of children (ages 6 months to 18 years) with
moderate-to-severe atopic dermatitis treated with either
Cutivate(R) Cream, a mid-potency topical steroid, or EpiCeram(TM).
The study was primarily conducted during the winter months of
December ('06), January ('07) and February ('07).

Primary and Secondary Outcome Measures.

According to the protocol, the primary outcome measure was the
change in mean SCORAD score measured at Day 28 as compared to the
baseline. The protocol's secondary efficacy parameters were:
-0-

a) Percentage of subjects reaching clear or almost clear on
Investigator's Global Assessment (IGA) at Day 28;
b) Change in patient reported assessments of pruritus (itch);
and
c) Change in patient reported assessment of disturbance of
sleep habits.

Daily (twice) applications of both Cutivate(R) Cream and
EpiCeram(TM) produced significant reductions in SCORAD scores at
Day 28 compared to baseline values. Daily (twice) applications of
EpiCeram(TM) produced statistically significant improvement of
atopic dermatitis after 28 days with a reduction in SCORAD scores
of 56.41% from baseline. Daily (twice) applications of the
comparator product, Cutivate(R) cream, also produced statistically
significant improvement of atopic dermatitis after 28 days with a
reduction in SCORAD scores of 68.77%. Statistical comparison of the
treatment effects (SCORAD scores) showed no statistically
significant difference between treatment effects after 28 days of
treatment.

Secondary Outcome Measures.

A. Percentage of subjects reaching clear or almost clear on IGA
at Day 28

Assessment of the disease progression showed significant
improvements in the IGA scores over time for both EpiCeram(TM) and
Cutivate(R) cream with 61.1% of the EpiCeram(TM) patients assessed
as clear or almost clear after 28 days of treatment and 76.2% of
the Cutivate(R) cream patients being assessed as clear or almost
clear at Day 28. Comparison of the disease progression results for
both treatments showed no statistically significant difference
between EpiCeram(TM) and Cutivate(R) cream after 28 days of
treatment.

B. Assessment of Pruritus.

Patient reported assessments of pruritus also showed significant
improvement from baseline after 28 days of treatment for both
EpiCeram(TM) (3.54 change from baseline) and Cutivate(R) cream
(3.75 change from baseline). No statistically significant
differences were found between treatments after 28 days of
treatment.

C. Assessment of Sleep Habits.

Patient reported assessments of sleep habits also showed
significant improvement from b
aseline after 28 days of treatment
for both EpiCeram(TM) (2.63 change from baseline) and Cutivate(R)
cream (2.81 change from baseline). No statistically significant
differences were found between treatments after 28 days of
treatment.

Safety

The investigators concluded that use of EpiCeram(TM) was safe
for use under the conditions of the study. There were no serious
adverse events reported in the study and all but one of the
reported adverse events either mild or moderate and all were
consistent with the symptoms of atopic dermatitis. The
investigators recommended that four EpiCeram(TM) patients
experiencing adverse events temporarily discontinue use of the
product. Two of these patients fully resolved. The investigators
made no recommendation that any of the Cutivate(R) patients
discontinue use.

About EpiCeram(TM)

EpiCeram(TM) is a prescription only product intended for use to
treat dry skin conditions and to manage and relieve the burning and
itching associated with various types of dermatoses including
atopic dermatitis (eczema), irritant contact dermatitis, and
radiation dermatitis. In April 2006, we received marketing
clearance from the FDA to sell EpiCeram(TM) as a medical device
pursuant to a 510(k) filing. Unlike steroids and immunomodulators,
both of which have well recognized undesirable side effects and
usage restrictions, EpiCeram(TM)'s non-steroidal formulation has a
very favorable safety profile and does not have the duration of use
restrictions or pediatric patient age restrictions of these other
classes of prescription products. Immunomodulator drugs used for
treating atopic dermatitis recently received a black box safety
warning from the FDA.

About Ceragenix

Ceragenix Pharmaceuticals, Inc. is a biopharmaceutical company
that discovers, develops and commercializes novel anti-infective
drugs based on its proprietary class of compounds, Ceragenins(TM)
(or CSAs). Active against a broad range of gram positive and
negative bacteria, these agents are being developed as
anti-infective medical device coatings (Ceracides(TM)) and as
therapeutics for antibiotic-resistant organisms. Ceragenix also
owns exclusive rights to Barrier Repair Technology for the
treatment of dermatological disorders including atopic dermatitis,
neonatal skin disorders and others. Ceragenix's patented Barrier
Repair Technology, invented by Dr. Peter Elias and licensed from
the University of California, is the platform for the development
of two prescription topical creams--EpiCeram(TM) and NeoCeram(TM).
For additional information on Ceragenix, please visit
www.ceragenix.com.

FORWARD LOOKING STATEMENTS

This press release may contain forward-looking statements. These
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
expressed or implied by such forward-looking statements, including,
but not limited to, the following: the ability of the company to
raise sufficient capital to finance its planned activities; the
ability of the company to satisfy its outstanding convertible debt
obligations; receiving the necessary marketing clearance approvals
from the United States Food and Drug Administration; successful
clinical trials of the company's planned products including; the
ability to enroll the studies in a timely manner, patient
compliance with the study protocol, and a sufficient number of
patients completing the studies; the ability of the company to
commercialize its planned products; the ability of the company to
consummate a favorable marketing agreement with a partner to market
EpiCeram(TM); market acceptance of the company's planned products,
the company's ability to successfully develop its licensed
compounds, alone or in cooperation with others, into commercial
products, the ability of the company to successfully prosecute and
protect its intellectual property, and the company's ability to
hire, manage and retain
qualified personnel. The aforementioned
factors do not represent an all inclusive list. Actual results,
performance or achievements could differ materially from those
contemplated, expressed or implied by the forward-looking
statements contained in this press release. In particular,
important factors that could cause actual results to differ
materially from the company's forward-looking statements include
general economic factors, business strategies, the state of capital
markets, regulatory conditions, and other factors not currently
known to the company, may be significant, now or in the future, and
these factors may affect the company to a greater extent than
indicated. All forward-looking statements attributable to the
company or persons acting on its behalf are expressly qualified in
their entirety by the cautionary statements set forth in this press
release and in other documents that the company files from time to
time with the Securities and Exchange Commission including its
Annual Report on Form 10-KSB for the year ended December 31, 2006,
Quarterly Reports on Form 10-QSB and Current Reports on Form 8-KSB
to be filed in 2007. Except as required by law, the company does
not undertake any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.

(Date:10/11/2017)... Oct. 11, 2017 BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...

(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their ... The patient is doing more than filling out a survey; in many cases health ... increasing emphasis in health care and research on the importance of active engagement with ...

(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...

(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...

(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...